LegoChem Biosciences, Inc.
http://www.legochembio.com/eng/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From LegoChem Biosciences, Inc.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Korean Vs Global Biopharma M&A Trends: How Different Are They?
A number of recent significant transactions in the South Korean biopharma space indicate some emerging trends as the sector develops and expands internationally. Scrip takes a look at the over-arching themes in M&A activity over the past few years and how these may differ from those being observed globally.
J&J Has An Appetite For Pharma M&A, But Knows What It Likes
CEO Joaquin Duato said J&J is agnostic on size when it comes to business development but has generally found more value creation in earlier-stage deals.
ADC Specialist LegoChem Takes Orion’s Hand As Long-Term Partner
Korean confectionery group Orion has become the biggest shareholder in compatriot ADC specialist LegoChem Biosciences, in a decisive step to move into the biotech sector as a new growth engine. For LegoChem, the alliance provides a friendly strategic partner and should enable a boost in R&D spending as it seeks to aggressively progress clinical trials and become a global player.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice